Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced that Dr. Douglas A. Lauffenburger has joined the speaker lineup for QSP Day 2018. The conference occurs Thursday, April 12, 2018 from 9:00 a.m. - 5:00 p.m. at the Samberg Conference Center, MIT Chang Building in Cambridge, MA.
Douglas A. Lauffenburger, PhD is a Ford Professor of Biological Engineering, Chemical Engineering, and Biology, as well as, head of the Department of Biological Engineering at Massachusetts Institute of Technology. Dr. Lauffenburger also serves as the chair of Applied BioMath's science advisory board.
In its second year, QSP Day is a full day event featuring talks from key industry and academic researchers, a poster session with awards, and networking time with peers. All registrants are welcome to submit posters in either the student or non-student categories. Three abstracts will be invited to give a 15 minute presentation during the conference. In addition, cash prizes will be awarded to the top three student posters, with first place receiving $1,000, second place receiving $500, and third place receiving $200.
"After witnessing the success of our first QSP Day last year, I look forward to bringing the QSP community together again to discuss the latest approaches of mathematical modeling in drug R&D," Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath
Additional speaker and agenda details will be announced closer to the event. For more information, to register, and to submit a poster, visit www.appliedbiomath.com/QSPDAY_2018.
About Applied BioMath
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, helps biotechnology and pharmaceutical companies answer complex, critical Go/No-go decisions in R&D. Applied BioMath leverages biology, proprietary mathematical modeling and analysis technology, high-performance computing, and decades of industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, and the best path forward. Our involvement shortens project timelines, lowers cost, and increases the likelihood of a best-in-class drug. We provide clarity to complex situations, answer otherwise unanswerable questions, and our approach, when validated in the clinic, is 10x more accurate than traditional methodologies.
Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.